ArcticZymes Technologies — Investor Presentation 2024

Sep 19, 2024

A Norwegian biotech growth ambitions

September 19, 2024 Pareto Healthcare Conference

CEO Michael Akoh CFO Børge Sørvoll

Overview Overview

A Norwegian biotech with growth potential A Norwegian biotech with growth ambitions

enzymes for advanced therapies and molecular Targeting segments with considerable growth potential World class products

A provider of novel

diagnostics

• World class R&D team • Novel enzymes for biomanufacturing and molecular research/diagnostics
• and strong manufacturing capabilities complying to both ISO13485 and GMP Margins above 90% across all products • Value of products supported by numerous publications
• No debt 250 NMOK in Listed on the Norwegian • Strong reputation in Molecular Tools and Biomanufacturing segments
• Cash reserve Stock Exchange • Net Promoter Score = 84

2

science tools companies, CDMO, Pharma and Tools and Bioprocessing The Market

World class products and reputation in Molecular

segments

US and Europe

• Targeting segments with high growth potential (MDx & CGT)

Customers are life

biotech

Headquartered in Tromsø

International management and Board

• Recuring revenue streams – sticky business Sales of 119 MNOK (2023), positive cash flow and results • Customers are life science tools, CDMO, Pharma and Biotech companies
• 55 employees, Direct sales force in the • Global nature with direct sales channels in the US (45%) & Europe (50%) ROW (5%)

Organisation

• 53 employees, HQ in Tromsø, Norway
• Experienced management team committed to creating a strong culture centered on commercialization of innovative solutions
• World class R&D team, strong and excellent manufacturing capabilities
• ISO13485 and GMP compliance

Strong Financials

• Margins > 90% on all products
• Sales of 119 MNOK (2023) and generating profit
• Recurring revenue streams potential – sticky business
• No debt 240 MNOK in Cash reserve
• Track record of 30yrs
• Listed on the Norwegian Stock Exchange

B2B Value chain Biomanufacturing and Molecular Tools customers

Biomanufacturing

Molecular Tools

Best-in-class Enzymes

Custom and OEM solutions – to meet customer's needs

Biomanufacturing (Therapeutics)

Viral vector, gene therapy and protein production

Removal of nucleic acids during protein production, vaccine manufacturing and viral vector preparation.

M-SAN HQ

Molecular Workflows (Research & Molecular Diagnostics)

SAN - Probably the best nuclease portfolio on the market

The right nuclease for the right application

• A single nuclease cannot meet the diverse demands of viral vector bioprocessing
• A diverse range of nucleases is essential there is no "one size fits all" solution in this market
• Our M-SAN nuclease is optimized for low-salt environments (~150 mM), ideal for Lenti vector production
• SAN HQ GMP is designed for high-salt conditions, typically around 500 mM or more, making it perfect for AAV vector production
• ArcticZymes offers one of the most versatile nuclease portfolios, covering the full spectrum of viral vector manufacturing needs
• Looking ahead, we will continue to innovate by launching two new GMP-grade nucleases within the next 12 months, expanding our leadership in the market

for physiological conditions 100 – 400 mM

SAN HQ / SAN HQ GMP

for high-salt conditions 400 – 1000 mM

Strategic priorities

Building a platform for long term growth – the journey has started

Thank you